Starve a Tumour, Feed a Cell: How Cancers Can Resist Drugs

Google+ Pinterest LinkedIn Tumblr +

With drug resistance a major challenge in the fight against cancer, a discovery by University of California, biologists could offer new approaches to overcoming the obstacle. Their research reveals that a mechanism enabling the diseased cells to scavenge dead cell debris for nourishment holds a pivotal role. The study by Aimee Edinger, associate professor of developmental & cell biology, and researcher Vaishali Jayashankar appears in Nature Communications.

“Cancer cells require a tremendous amount of nutrients,” Edinger said. “Chemotherapy and other treatments that damage DNA force tumour cells to rev up their metabolism to make the repairs necessary to survive and grow. Targeting DNA metabolism in this way often works for a while, but in virtually all patients, tumour cells become resistant and the treatment becomes ineffective.”

In probing the problem, the two scientists examined a process called macropinocytosis. It enables a cancer cell desperate for nourishment to scoop up dead cell material within a tumour and feed on it.

“Tumours contain a lot of dead cells because the blood supply is abnormal, causing many cancer cells to starve to death,” Edinger said. “Using this method of scavenging, cancer cells can obtain the amino acids, sugars, fatty acids and nucleotides they require to keep growing.”

This new research revealed that macropinocytosis makes a previously unappreciated contribution to breast cancer drug-resistance. Edinger and Jayashankar also demonstrated that the same process could thwart treatments for pancreas and prostate cancer.

“What we see is that blocking macropinocytosis can help us to treat many different cancers more effectively,” Edinger said. “This knowledge could enable better biomarker selection in clinical drug trials currently underway, leading to improved response to pharmaceutical combinations. It also provides a strong rationale for developing drugs that target and block macropinocytosis.”


Paper: Vaishali Jayashankar, Aimee L. Edinger. Macropinocytosis confers resistance to therapies targeting cancer anabolism. Nature Communications, 2020; 11 (1) DOI: 10.1038/s41467-020-14928-3

Source: University of California – Irvine

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.